Statins and C-reactive protein: Considering a novel marker of cardiovascular risk

Preventive Cardiology

Volumn 5, Issue 4, 2002, Pages 200-203

  Gotto Jr , Antonio M ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE PHASE PROTEIN; ATORVASTATIN; C REACTIVE PROTEIN; CERIVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 1; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PLACEBO; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CORONARY RISK; DISEASE MARKER; DRUG EFFICACY; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; INFLAMMATION; PRIMARY PREVENTION; REVIEW;

EID: 0036752796     PISSN: 1520037X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1520.037X.2002.01489.x     Document Type: Review

References (25)

1. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;334:1383-1389.
2. Sacks FM, Pfeffer MA, Moye L, et al., for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001-1009.
3. Shepard J, Cobb SM, Ford I, et al., for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301-1307.
4. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events in men and women with average cholesterol levels. JAMA. 1998;279:1615-1622.
5. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Intervention Trials Group. N Engl J Med. 1999;341(6):410-418.
6. Expert Panel on the Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486-2497.
7. Schoenhagen P, Ziada KM, Vince DG, et al. Arterial remodeling and coronary artery disease: The concept of "dilated" versus "obstructive" coronary atherosclerosis. J Am Coll Cardiol. 2001;38(2):297-306.
8. Fayad ZA, Fuster V. Clinical imaging of the high-risk or vulnerable atherosclerotic plaque. Circ Res. 2001;89(4):305-316.
9. Guerci AD, Arad Y. Potential use of Ca++ scanning to determine the need for and intensity of lipid-lowering therapy in asymptomatic adults. Curr Cardiol Rep. 2001;3(5):408-415.
10. Ross R. Atherosclerosis: An inflammatory disease. N Engl J Med. 1999;340:115-126.
11. Munford RS. Statins and the acute-phase response. N Engl J Med. 2001;344:2016-2018.
12. Libby P, Ridker PM. Novel inflammatory markers of coronary risk. Circulation. 1999;100:1148-1150.
13. Rifai N, Tracy RP, Ridker PM. Clinical efficacy of an automated high sensitivity C-reactive protein assay. Clin Chem. 1999;45:2136-2141.
14. Morrow DA, Rifai N, Antman E, et al. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: A TIMI 11A substudy. J Am Coll Cardiol. 1998;31:1460-1465.
15. Danesh J, Whincup P, Walker M, et al. Low grade inflammation and coronary heart disease: Prospective study and up-dated meta-analyses. BMJ. 2000;321:199-204.
16. Mendall MA, Strachan DP, Butland BK, et al. C-reactive protein: Relation to total mortality, cardiovascular mortality and cardiovascular risk factors in men. Eur Heart J. 2000;21:1584-1590.
17. Ridker PM, Rifai N, Pfeffer MA, et al., for the Cholesterol and Recurrent Events (CARE) Investigators. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation. 1998;98:839-844.
18. Ridker PM, Rifai N, Pfeffer MA, et al. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation. 1999;100:230-235.
19. Ridker PM, Rifai N, Clearfield M, et al., for the Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med. 2001;344:1959-1965.
20. Albert MA, Danielson E, Rifai N, et al. Effect of statin therapy on C-reactive protein levels, the Pravastatin lnflammation/CRP Evaluation (PRINCE): A randomized trial and cohort study. JAMA. 2001;286:64-70.
21. Jialal I, Stein D, Balis D, et al. Effect of hydroxymethyl-glutaryl coenzyme A reductase inhibitor therapy on high-sensitivity C-reactive protein levels. Circulation. 2001;103:1933-1935.
22. Ridker PM, Rifai N, Lowenthal SP. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation. 2001;103:1191-1193.
23. Miller M, Jialai I. Effects of simvastatin (40 and 80 mg) on highly sensitive C-reactive protein in patients with combined hyperlipidemia. Am J Cardiol. 2002;89:468-469.
24. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation. 2001;104:365-372.
25. Sparrow CP, Burton CA, Hernandez M, et al. Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering. Arterioscler Thromb Vasc Biol. 2001;21:115-121.